2. Search Result
Search Result
Results for "

CDK2 inhibitor

" in MedChemExpress (MCE) Product Catalog:

237

Inhibitors & Agonists

1

Peptides

8

Natural
Products

3

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15339
    CVT-313
    5+ Cited Publications

    CDK2 inhibitor III

    		 CDK Cancer
    CVT-313 (Cdk2 Inhibitor III) is a potent, selective, reversible, and ATP-competitive inhibitor of CDK2 with IC50 of 0.5 μM. CVT-313 inhibits CDC5L phosphorylation .
    CVT-313
  • HY-157516
    CDK2-IN-22

    		CDK Cancer
    CDK2-IN-22 (compound 7I) is a potent CDK2 inhibitor with an IC50 of 64.42 nM. CDK2-IN-22 presents a broad antiproliferative efficacy toward diverse cancer cells MV4-11, HT-29, MCF-7, and HeLa with IC50 values of 0.83 μM, 2.12 μM, 3.12 μM, and 8.61 μM, respectively .
    CDK2-IN-22
  • HY-148651
    CDK2-IN-15

    		CDK Cardiovascular Disease Cancer
    CDK2-IN-15 (Compound 19) is an inhibitor of CDK2 with an IC50 of 2.9 μM. CDK2-IN-15 can be used for cancer research .
    CDK2-IN-15
  • HY-155441
    CDK2-IN-20

    		CDK Cancer
    CDK2-IN-20 (compound 3b) is an inhibitor of CDK2. CDK2-IN-20 has cytotoxicity on tumor cells presenting an IC50 range of 5.52-17.09 µM. CDK2-IN-20 arrests the MCF-7 cell cycle at the S phase and induces apoptosis .
    CDK2-IN-20
  • HY-163357
    CDK2/MDM2-IN-1

    		CDK MDM-2/p53 Cancer
    CDK2/MDM2-IN-1 (III-13) is a dual inhibitor of CDK2/MDM2 with an IC50 value of 2.60 nM for CDK2. CDK2/MDM2-IN-1 has antitumor activity .
    CDK2/MDM2-IN-1
  • HY-162270
    CDK2-IN-24

    		CDK Cancer
    CDK2-IN-24 (compound 3f) is an inhibitor of cyclin-dependent kinase 2 with an elevated binding energy value .
    CDK2-IN-24
  • HY-144810
    CDK2-IN-8

    		CDK Cancer
    CDK2-IN-8 is a potent CDK2 inhibitor with an IC50 of 1.74 µM. CDK2-IN-8 shows antiproliferative activity. CDK2-IN-8 has the potential for the research of melanoma .
    CDK2-IN-8
  • HY-W478102S
    CDK2-IN-13-d3

    		Isotope-Labeled Compounds CDK Cancer
    CDK2-IN-13-d3 is the deuterium labeled CDK2-IN-13 (HY-W478102). CDK2-IN-13 (Compound 15) is a CDK2 inhibitor with an IC50 of 12 μM. CDK2-IN-13 can be used in research of cancer .
    CDK2-IN-13-d3
  • HY-160643
    CDK2-IN-27

    		CDK Cancer
    CDK2-IN-27 (compound 1) is a potent CDK2 inhibitor with IC50 values of <10, >10-20 nM for CDK2/cyclin E1, CDK2/cyclin B1, respectively .
    CDK2-IN-27
  • HY-170897
    CDK2-IN-40

    		CDK Cancer
    CDK2-IN-40 is a CDK2 (Cyclin dependent kinase 2) inhibitor, extracted from patent WO 2024/254245 A1 (Example 1). CDK2-IN-40 inhibits CDK2/Cyclin E1 with an IC50 of ≤ 10 nM .
    CDK2-IN-40
  • HY-169683
    CDK2-IN-39

    		CDK Cancer
    CDK2-IN-39 (compound 4) is a CDK2 inhibitor .
    CDK2-IN-39
  • HY-151580
    CDK2-IN-14

    		CDK Cancer
    CDK2-IN-14 (compound 4f) is a highly selective CDK2 inhibitor. CDK2-IN-14 can be used in research of cancer .
    CDK2-IN-14
  • HY-W478102
    CDK2-IN-13

    		CDK Cancer
    CDK2-IN-13 (Compound 15) is a CDK2 inhibitor with an IC50 of 12 µM. CDK2-IN-13 can be used in research of cancer .
    CDK2-IN-13
  • HY-164664
    CDK2-IN-30

    		CDK Cancer
    CDK2-IN-30 (Formula (I)) is a CDK2 inhibitor with an IC50 value ≤20 nM. CDK2-IN-30 can be used in tumor research .
    CDK2-IN-30
  • HY-159805
    CDK2-IN-31

    		CDK Cancer
    CDK2-IN-31 (compound I-125A) is a CDK2 inhibitor. CDK2-IN-31 can be used in cancer research .
    CDK2-IN-31
  • HY-162255
    CDK2-IN-23

    		CDK Cancer
    CDK2-IN-23 (Compound 17) is a kinase selective and highly potent CDK2 inhibitor (IC50 = 0.29 nM). CDK2-IN-23 shows the pharmacodynamic inhibition of CDK2 in CCNE1-amplified mouse models. CDK2-IN-23 can be used for the research of cancer .
    CDK2-IN-23
  • HY-139651
    CDK2-IN-7

    		CDK Cancer
    CDK2-IN-7 is a CDK2 inhibitor for researching cancer (IC50 < 50 nM).
    CDK2-IN-7
  • HY-160556
    CDK2-IN-26

    		CDK Cancer
    CDK2-IN-26 (compound 9) is a potent inhibitor of CDK2 .
    CDK2-IN-26
  • HY-144811
    CDK2-IN-9

    		CDK Apoptosis Cancer
    CDK2-IN-9 is a potent CDK2 inhibitor with an IC50 of 0.63 µM. CDK2-IN-9 shows antiproliferative activity. CDK2-IN-9 induces apoptosis and cell cycle arrest at S and G2/M phase. CDK2-IN-9 has the potential for the research of melanoma .
    CDK2-IN-9
  • HY-170441
    CDK2-IN-36

    		CDK Cancer
    CDK2-IN-36 (compound1) is a CDK2 inhibitor with anticancer activity .
    CDK2-IN-36
  • HY-151580S
    CDK2-IN-14-d3

    		CDK Cancer
    CDK2-IN-14-d3 is a potent and selective CDK2 inhibitor. CDK2-IN-14-d3 can be used in research of cancer .
    CDK2-IN-14-d3
  • HY-150573
    CDK2-IN-12

    		CDK Carbonic Anhydrase Cancer
    CDK2-IN-12 (compound 10b) is a potent CDK2 inhibitor, with an IC50 of 11.6 μM. CDK2-IN-12 inhibits hCA (carbonic anhydrase) isoforms I, II, IX and XII, with KI values of 3534, 638.4, 44.3, and 48.8 nM. CDK2-IN-12 shows anticancer activity .
    CDK2-IN-12
  • HY-173203
    CDK2-IN-43

    		CDK Cancer
    CDK2-IN-43 (Compound 3a) is a CDK2-cyclin E2 inhibitor with an IC50 value of 6.0 nM. CDK2-IN-43 can be used in the research of the anti-cancer field .
    CDK2-IN-43
  • HY-112460
    CDK2-IN-3

    		CDK Cancer
    CDK2-IN-3 (compound 3) is a potent and selective CDK2 inhibitor with an IC50 of 60 nM .
    CDK2-IN-3
  • HY-155966
    CDK2-IN-19

    		CDK Cancer
    CDK2-IN-19 (Compound 32) is a selective and orally active CDK2 inhibitor (Ki: 0.18 nM). CDK2-IN-19 shows anticancer activity in mice bearing OVCAR3 tumors .
    CDK2-IN-19
  • HY-161291
    CDK2-IN-25

    		CDK Cancer
    CDK2-IN-25 (compound 7e) is a CDK2 inhibitor with an IC50 of 0.149 μM .
    CDK2-IN-25
  • HY-172872
    CDK2-IN-45

    		CDK Apoptosis Cancer
    CDK2-IN-45 (Compound 8f) is a CDK2 inhibitor (IC50: 0.64 μM). CDK2-IN-45 inhibits the proliferation of DU-145 and PC-3 cell lines with IC50 of 2.20 μM and 4.17 μM, respectively. CDK2-IN-45 induces G0/G1 cell cycle arrest and apoptosis. CDK2-IN-45 can be used in prostate cancer research .
    CDK2-IN-45
  • HY-169246
    CDK2-IN-32

    		CDK Apoptosis Cancer
    CDK2-IN-32 (Compound 5g) is a selective CDK2 inhibitor with an IC50 of 0.21 μM. CDK2-IN-32 shows cytotoxicity against Vero cells with an IC50 of 28.52 μM .
    CDK2-IN-32
  • HY-155602
    CDK2-IN-18

    		CDK Cancer
    CDK2-IN-18 (compound 8q) is a potent inhibitor of CDK2/E and CDK4/D1, with IC50s of 8 nM and 46 nM, respectively. CDK2-IN-18 inhibits the proliferation of tumor cells .
    CDK2-IN-18
  • HY-170442
    CDK2-IN-37

    		CDK Cancer
    CDK2-IN-37 (COMPOUND 2) is a cyclin-dependent kinase (CDK2) inhibitor with anti-cancer activity .
    CDK2-IN-37
  • HY-176174S
    CDK2-IN-46

    		Isotope-Labeled Compounds CDK Cancer
    CDK2-IN-46 (compound 5g) is a selective CDK2 inhibitor with an IC50 of 0.3 nM. CDK2-IN-46 has a selectivity of >200-fold for CDK1, CDK7, CDK9, CDK4, and CDK6. CDK2-IN-46 shows improves rat and cyno pharmacokinetic profiles .
    CDK2-IN-46
  • HY-173310
    CDK2-IN-44

    		CDK Cancer
    CDK2-IN-44 (Compound 46) is an inhibitor of cyclin-dependent kinase 2 (CDK2). CDK2-IN-44 can effectively inhibit the proliferation of cancer cells and exert its activity in inhibiting cancer cell growth by arresting the cell cycle, promoting Apoptosis, and inducing cellular senescence. CDK2-IN-44 holds promise for use in the research of ovarian cancer and breast cancer .
    CDK2-IN-44
  • HY-168057
    PROTAC CDK2 Degrader-1

    		PROTACs CDK Cancer
    PROTAC CDK2 Degrader-1 (Compound 41) is a PROTAC degrader for cyclin-dependent kinase 2 (CDK2). PROTAC CDK2 Degrader-1 inhibits the phosphorylation of RB protein in CDK2 dependent cell line OVCAR3 with an IC50 of 100-500 nM .
    PROTAC CDK2 Degrader-1
  • HY-161463
    CDK2-IN-28

    		CDK Cancer
    CDK2-IN-28 (compound 22) is a CDK2 inhibitor with good selectivity and cellular effects against other CDKs. CDK2-IN-28 has anti-proliferative effects on MKN1 cells (EC50: 0.31 μM) .
    CDK2-IN-28
  • HY-159155
    CDK2/4-IN-1

    		CDK Microtubule/Tubulin Cancer
    CDK2/4-IN-1 (compound B-4a) is a CDK2/4 inhibitor and a tubulin polymerization inhibitor. CDK2/4-IN-1 can be used in cancer research .
    CDK2/4-IN-1
  • HY-172153
    CDK2-IN-41

    		CDK Reactive Oxygen Species (ROS) Apoptosis Cancer
    CDK2-IN-41 (Compound 7a) is a CDK2 inhibitor that exerts anticancer activity by binding to CDK2, thereby inhibiting the cell cycle, inducing cytotoxicity, promoting ROS production, and triggering Apoptosis. CDK2-IN-41 exhibits an IC50 of 10 µM against acute myeloid leukemia (AML) HL-60 cells. It holds potential for research in AML-related cancer therapy .
    CDK2-IN-41
  • HY-151573
    EGFR/CDK2-IN-1

    		EGFR CDK Cancer
    EGFR/CDK2-IN-1 (Compound 3b) is an EGFR/CDK2 inhibitor. EGFR/CDK2-IN-1 shows good cytotoxicity against MCF7 and HepG2 cells. EGFR/CDK2-IN-1 can be used in cancer research .
    EGFR/CDK2-IN-1
  • HY-173224
    CDK2/PIM1-IN-1

    		CDK Pim Cancer
    CDK2/PIM1-IN-1 is an inhibitor of CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM) kinases. CDK2/PIM1-IN-1 induces apoptosis and reduces tumor-promoting TNF-α expression. CDK2/PIM1-IN-1 has antitumor activity .
    CDK2/PIM1-IN-1
  • HY-117535
    CDK2-IN-4
    2 Publications Verification

    		 CDK Cancer
    CDK2-IN-4 (compound 73) is a potent and selective CDK2 inhibitor with an IC50 of 44 nM for CDK2/cyclin A, shows 2,000-fold selectivity over CDK1/cyclin B (IC50=86 uM) .
    CDK2-IN-4
  • HY-169048
    CDK2/4-IN-2

    		CDK Cancer
    CDK2/4-IN-2 (compound 56) is a CDK2 and CDK4 dual inhibitor with IC50s less than 100 nM. CDK2/4-IN-2 can be used in the study of cancer .
    CDK2/4-IN-2
  • HY-150572
    CDK2-IN-11

    		CDK Carbonic Anhydrase Cancer
    CDK2-IN-11 (compound 9d) is a potent CDK2 inhibitor with an IC50 of 6.4 μM, and KI values of 23.4 nM, 56.3 nM and 44.3 nM for hCA II, hCA IX and hCA XII, respectively. CDK2-IN-11 can be used for researching anticancer .
    CDK2-IN-11
  • HY-149436
    CDK2/Bcl2-IN-1

    		CDK Cancer
    CDK2/Bcl2-IN-1 (compound 1), a saponin and a CDK-2 inhibitor (IC50=117.6 nM) with promising cytotoxicity against cancer cells. CDK2/Bcl2-IN-1 also inhibits Bcl-2, and induces apoptosis in A549 lung cancer cells .
    CDK2/Bcl2-IN-1
  • HY-P3731
    Cdk2/Cyclin Inhibitory Peptide II

    		CDK Cancer
    Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a CDK2 inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .
    Cdk2/Cyclin Inhibitory Peptide II
  • HY-P3730
    Cdk2/Cyclin Inhibitory Peptide I

    		CDK Cancer
    Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG), a CDK2 inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .
    Cdk2/Cyclin Inhibitory Peptide I
  • HY-143497
    HDAC1/2 and CDK2-IN-1

    		HDAC CDK Apoptosis Cancer
    HDAC1/2 and CDK2-IN-1 (compound 14d) is a potent HDAC1, HDAC2 and CDK2 dual inhibitor, with IC50 values of 70.7, 23.1 and 0.80 μM, respectively. HDAC1/2 and CDK2-IN-1 can block the cell cycle and induce apoptosis. HDAC1/2 and CDK2-IN-1 exhibits desirable in vivo antitumor activity .
    HDAC1/2 and CDK2-IN-1
  • HY-123045
    PNU-292137

    		CDK Cancer
    PNU-292137 is an orally active, potent CDK2 inhibitor with IC50s of 37 nM and 92 nM for CDK2/cyclin A and CDK2/cyclin E, respectively. PNU-292137 makes interactions with the hydrophobic pocket at the back of the CDK2 ATP pocket. PNU-292137 efficiently inhibits tumor cell proliferation in human colon and prostate tumor cell lines. PNU-292137 exhibits antitumor activity (TGI>50%) in a mouse xenograft model .
    PNU-292137
  • HY-156116
    EGFR/CDK2-IN-4

    		EGFR CDK Cancer
    EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor of EGFR and CDK-2 with IC50s of 89.6 and 165.4 nM, respectively. EGFR/CDK2-IN-4 induces apoptosis in MCF-7 cells and arrests the cell cycle in the S phase. EGFR/CDK2-IN-4 has significant anti-cancer cell toxicity and inhibits MCF-7 with an IC50 of 2.74 μM .
    EGFR/CDK2-IN-4
  • HY-156115
    EGFR/CDK2-IN-3

    		EGFR CDK Cancer
    EGFR/CDK2-IN-3 (compound 4b) is a dual inhibitor of EGFR and CDK-2 with IC50s of 71.7 and 113.7 nM, respectively. EGFR/CDK2-IN-3 induces apoptosis in MCF-7 cells and arrests the cell cycle in the S phase. EGFR/CDK2-IN-3 has significant anti-cancer cell toxicity and inhibits MCF-7 with an IC50 of 3.16 μM .
    EGFR/CDK2-IN-3
  • HY-156114
    EGFR/CDK2-IN-2

    		EGFR CDK Cancer
    EGFR/CDK2-IN-2 (compound 6a) is a dual inhibitor of EGFR and CDK-2 with IC50s of 19.6 and 87.9 nM, respectively. EGFR/CDK2-IN-2 induces apoptosis in MCF-7 cells and arrests the cell cycle in the S phase. EGFR/CDK2-IN-2 has significant anti-cancer cell toxicity and inhibits MCF-7 with an IC50 of 0.39 μM .
    EGFR/CDK2-IN-2
  • HY-15004
    AUZ 454
    5 Publications Verification

    K03861

    		 CDK Cancer
    AUZ 454 (K03861) is a type II CDK2 inhibitor with Kd of 8.2 nM. AUZ 454 (K03861) inhibits CDK2 activity by competing with binding of activating cyclins.
    AUZ 454

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: